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OBJECTIVES: According to the Swedish Healthcare Act, any decisions for prioriti-
sation in health care should be based on three principles; the principle of human
dignity, the principle of need and solidarity, and the principle of cost-effectiveness.
The principle of human dignity is superior to the two other principles and the
cost-effectiveness principle is subordinate to the other two. The Swedish Dental
and Pharmaceutical Benefits Agency (TLV) must prioritise accordingly when as-
sessing whether a pharmaceutical should belong to the reimbursement system.
This study aims to investigate the importance of economic evaluations in decisions
for admission of pharmaceuticals to the reimbursement scheme. METHODS: A
review of all TLV decisions regarding admission to the reimbursement system
dated January 2011 to March 2012 was conducted. The information extracted in-
cluded e.g. decision outcome, type of economic evaluation employed and consid-
ered medical need. Subsequently, the reasons behind the decisions were analysed.
RESULTS:A total of 100 individual decisions for reimbursement were assessed. The
vast majority of the 69 decisions leading to general reimbursement were made
based on the result of an economic evaluation and a great medical need was the
second most important reason. All of the eight negative decisions referred to the
inability of the product to be considered a cost-effective alternative. The main
reasons behind the 23 decisions for restricted reimbursement were a great medical
need and that the product was cost-effective alternative for a specific subgroup.
Hence, it appears that the principle for cost-effectiveness is considered more im-
portant than the principle of human dignity as medical need was the second most
common reason for general reimbursement. CONCLUSIONS: The principle for
cost-effectiveness appears to be the most important principle in decisions around
a pharmaceutical’s admission to the reimbursement system, although the princi-
pal’s subordinate position to the principle of human dignity and the principle of
need and solidarity.
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REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS
(2007-2012)
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends, we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales) METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase “cost effectiveness” in abstract of the published
study. RESULTS: During 2007-2012, the number of published studies on “cost ef-
fectiveness” have increased by more than 32%. There is a large variability in CERs
for same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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THE SHARP DECREASE OF DRUG’S ACCESS TO REIMBURSEMENT IN FRANCE IN
2011
Hounkanlin H, Troubat A, Morlet Vigier D
IMS Health, Puteaux, France
OBJECTIVES: In France, all drug’s indications are listed for reimbursement accord-
ing to the advice of the Haute Autorité de Santé (HAS), which assesses the SMR level
(Service Medical Rendu) – linked to the future drug reimbursement level, the ASMR
(comparative added value) – linked to the future price and “official” target popula-
tion. Until last year, 90-95% of SMR levels allowed reimbursement, hence a signif-
icant manufacturer focus on ASMR level (which actually is the basis for reimbursed
drugs price fixation). Following the “Mediator affair” in 2010, the HAS perceived
high percentage of positive recommendations for reimbursement have been chal-
lenged by multiple administrative and political reports. We investigated the 2011
HAS recommendations for reimbursement of new drugs/indications. METHODS:
We considered all complete procedures for a first inscription or line extension with
an HAS opinion published between Jan and Dec 2011. We also considered applica-
tions which have been withdrawn by companies (no HAS advice). We focused our
analysis on the SMR level, indication by indication, and compared it to 2010 HAS
opinions. RESULTS: Sixty-two HAS opinions have been published in 2011: 30% less
than in 2010 (85 opinions in 2010). Regarding the SMR and considering it is granted
indication by indication: out of 81 SMRs granted for a first indication reimburse-
ment, 30% (24) were considered “insufficient” (no reimbursement)–in 11 of these
cases companies withdrew their applications. In 2010, the SMR “insufficient” rep-
resented only 11% of all the published advices (which was already higher than 2009:
6%). CONCLUSIONS: The number of positive recommendations for reimbursement
has sharply decreased in 2011 versus 2010, going from 6-10% in previous years to
over 30%. A qualitative analysis shows that the HAS seems to have evolved the
assessment criteria used for SMR.
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ORPHAN DRUG PRICING AND ACCESS – CURRENT SITUATION AND FUTURE
TRENDS IN EU
Jeffery M, White R
Access Partnership, London, UK
OBJECTIVES: In recent years, several European countries have made changes to
their policies related to HTA, pricing and market access, funding and cost reduc-
tion. This has impacted orphan drugs and this will continue in the future. The
objective of this research is to assess the current and future orphan drug pricing
and reimbursement environment analyzing the changing dynamics from all
perspectives.METHODS: Interviews were conducted with a variety of stakeholders
including payers, academics, and KOLs in France, Italy, Germany, Spain, the UK,
Sweden, Romania, Poland and the Netherlands. Comparisons were also made with
other mature markets such as Australia, and the US. RESULTS: Orphan definitions
vary from 5 in 10,0000 in EU to 1.2 in 10,000 in Australia. Pricing, payment and
regulations mechanisms demonstrate variability across countries including finan-
cial incentives, protocol assistance, fast-track procedures and market exclusivity.
There is lack of clarity at the EU as well as country level. For instance according to
AMNOG law in Germany, products with less than €50 million budget impact are not
expected to be assessed. However IQWiG did assess orphan drugs in 2011-12. In the
UK, with the introduction of value based pricing in 2014, orphan drug approvals are
likely to improve. The number of orphan drug approvals and the share of pharma-
ceutical spend will increase with as much as 1-2% absolute, current levels being at
approximately 3%. However this may not translate into disproportionate drug
expenditure. Regulatory as well as payers have been accommodative in accepting
sub-optimal clinical data; however in the future this is expected to change.
CONCLUSIONS: Payers are expected to become sensitive to orphan drug data re-
quirements. The drivers of pricing and reimbursement decision will remain the
same at unmet need, disease severity and number of patients; however the ex-
pected magnitude of clinical effectiveness of the drug will be higher.
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SMC DECISIONS: ARE THEY GETTING TOUGHER?
Morawski J
Quintiles Consulting, Hoofddorp, The Netherlands
OBJECTIVES: To investigate whether trends exist in NHS drug funding decisions in
Scotland over recent years.METHODS: In 2008, the Scottish Medicines Consortium
(SMC) published an annual report illustrating drug submission statistics for that
year. No further annual reports or related data has been published by the SMC since
then. In the absence of such reports, a quantitative analysis was performed includ-
ing all SMC appraisals published between January 2008 and December 2011 to
investigate whether any trends exist in the decisions rendered by the SMC. The
analysis was first performed on all submissions in total and then by submission
type. RESULTS: On average 80 (range 73 – 88) submission assessments were per-
formed by the SMC per year. The proportion of decisions granted by the SMC over
the four years was relatively stable with an average of 37%/ 32%/ 31% accounting for
full recommendations/ restricted recommendations and non-recommendations.
In the abbreviated submission process, the proportion of recommended submis-
sions has decreased gradually (20 [80%] abbreviated submissions in 2008 to 8 [50%]
in 2011) with a parallel increase in restricted recommendations (4 [16%] in 2008 to
8 [50%] in 2011). The number of non-submissions has also increased progressively
over the last three years, accounting for 19% of assessments performed by the SMC
in 2011. High variations in the proportion recommendations (range 14 – 38%) and
restricted recommendations (range 11 – 43%) granted for resubmissions were ob-
served across the years. CONCLUSIONS: The analysis shows that over the four
years investigated, the proportion of recommendations, restricted recommenda-
tions and non-recommendations granted for reimbursement submissions in Scot-
land remained fairly consistent. At a closer look, clear trends were evident for
abbreviated submission decisions. Eventually around 85% of SMC submissions will
receive funding through either a full recommendation, restricted recommendation
or resubmission recommendation.
PHP118
ESTIMATING THE PROBABILITY OF A RECOMMENDATION FOR
REIMBURSEMENT FOR A NEW DRUG IN THE UK USING AN MCDA APPROACH
Williams P1, Mauskopf JA1, Kilburg A2, Lebiecki J2
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OBJECTIVES: To develop a quantitative process to estimate the probability of a
recommendation for reimbursement for a new drug with a cost per QALY of be-
tween 20,000 and 30,000 pounds in the UK.METHODS:A multi-criteria process was
used that included: selection of 7 UK decision makers; pre-workshop question-
naires to identify the most important attributes for the decision and their relative
importance; a workshop to develop levels for the most important attributes, map
each attribute level to a value function and identify marginal drug profiles (drugs
just acceptable for a recommendation for reimbursement); post-workshop estima-
tion of weighted scores for each marginal product based on the estimated values
and relative importance of their attribute levels and a logistic regression model to
estimate the probability of a favorable reimbursement recommendation as a func-
tion of the weighted scores; post-workshop questionnaire to validate the logistic
model using participant ratings for a series of hypothetical products. RESULTS:The
most important attributes identified for a recomendation for reimbursement and
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